Resultados de procura - Keith T. Flaherty

Limitar resultados
  1. 1
    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma por Keith T. Flaherty

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    MAP kinase signaling and inhibition in melanoma

    MAP kinase signaling and inhibition in melanoma por Ryan J. Sullivan, Keith T. Flaherty

    Publicado 2012
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance por Ryan J. Sullivan, Keith T. Flaherty

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    BRAF, a target in melanoma

    BRAF, a target in melanoma por Keith T. Flaherty, Grant A. McArthur

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    Integrating BRAF/MEK inhibitors into combination therapy for melanoma

    Integrating BRAF/MEK inhibitors into combination therapy for melanoma por Keiran S.M. Smalley, Keith T. Flaherty

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  6. 6
    Targeting the RAS pathway in melanoma

    Targeting the RAS pathway in melanoma por Zhenyu Ji, Keith T. Flaherty, Hensin Tsao

    Publicado 2011
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways por Xue Bai, David E. Fisher, Keith T. Flaherty

    Publicado 2019
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    YAP in MAPK pathway targeted therapy resistance

    YAP in MAPK pathway targeted therapy resistance por Keith T. Flaherty, Jennifer A. Wargo, Trever G. Bivona

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  9. 9
    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy por Jennifer A. Lo, David E. Fisher, Keith T. Flaherty

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be

    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be por Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

    Publicado 2013
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  11. 11
    Mutation-driven drug development in melanoma

    Mutation-driven drug development in melanoma por Keith T. Flaherty, F. Stephen Hodi, Boris C. Bastian

    Publicado 2010
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  12. 12
    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer por Jennifer A. Wargo, Zachary A. Cooper, Keith T. Flaherty

    Publicado 2014
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  13. 13
    Melanoma: New Insights and New Therapies

    Melanoma: New Insights and New Therapies por Vasiliki Nikolaou, Alexander Stratigos, Keith T. Flaherty, Hensin Tsao

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  14. 14
    Mechanisms of resistance to immune checkpoint inhibitors

    Mechanisms of resistance to immune checkpoint inhibitors por Russell W. Jenkins, David A. Barbie, Keith T. Flaherty

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  15. 15
    The Conundrum of Genetic “Drivers” in Benign Conditions

    The Conundrum of Genetic “Drivers” in Benign Conditions por Shumei Kato, Scott M. Lippman, Keith T. Flaherty, Razelle Kurzrock

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  16. 16
    Precision medicine for cancer with next-generation functional diagnostics

    Precision medicine for cancer with next-generation functional diagnostics por Adam A. Friedman, Anthony Letai, David E. Fisher, Keith T. Flaherty

    Publicado 2015
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  17. 17
    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma por Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay Srivastava

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition por Zhenyu Ji, Ching Ni Njauw, Michael Taylor, Victor Neel, Keith T. Flaherty, Hensin Tsao

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape por Inna V. Fedorenko, Jennifer A. Wargo, Keith T. Flaherty, Jane L. Messina, Keiran S.M. Smalley

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    A Melanoma Molecular Disease Model

    A Melanoma Molecular Disease Model por Smruti J. Vidwans, Keith T. Flaherty, David E. Fisher, Jay M. Tenenbaum, Michael Travers, Jeff Shrager

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: